Author(s): Nichols WG, Peck Campbell AJ, Boeckh M, Nichols WG, Peck Campbell AJ, Boeckh M
Abstract Share this page
Abstract Though several antivirals have been developed and marketed to treat influenza virus infections, the development of antiviral agents with clinical activity against other respiratory viruses has been more problematic. Here we review the epidemiology of respiratory viral infections in immunocompetent and immunocompromised hosts, examine the evidence surrounding the currently available antivirals for respiratory viral infections other than influenza, highlight those that are in the pipeline, and discuss the hurdles for development of such agents.
This article was published in Clin Microbiol Rev
and referenced in Medical Safety & Global Health